WHO 2级脑膜瘤早期与晚期放疗结局:TROD神经肿瘤组全国回顾性分析
该多中心回顾性队列纳入2005至2023年263例成人WHO 2级脑膜瘤患者,比较早期辅助放疗与进展后晚期放疗的长期结局。中位随访超过7年,早期放疗显著改善无进展生存(10年PFS 84.8% vs 18.6%,p<0.001),全切亚组同样获益(89.3% vs 18.8%),但总生存无显著差异。
要点
- 早期放疗较晚期放疗显著延长WHO 2级脑膜瘤的无进展生存。
- 全切术后早期放疗10年PFS仍达89.3%,晚期放疗仅18.8%。
- 肿瘤相关死亡晚期放疗组约高六倍,但全因死亡无显著差异。
核心结论
- 在WHO 2级脑膜瘤中,早期放疗较晚期放疗提供持久且有临床意义的PFS获益,包括全切术后,但未带来OS优势。
研究设计与样本
- 多中心回顾性队列研究,纳入2005至2023年263例病理确诊的成人WHO 2级脑膜瘤患者,按放疗时机分为早期辅助放疗组与进展后晚期放疗组。
主要发现
- 中位随访超过7年,总体队列10年PFS早期放疗为84.8%,晚期放疗为18.6%(p<0.001)。
- 全切亚组10年PFS早期放疗为89.3%,晚期放疗为18.8%(p<0.001)。
- 肿瘤相关死亡率晚期放疗组约高六倍(16.7% vs 2.7%,p=0.011),全因死亡率无显著差异(24.2% vs 14.7%,p=0.198)。
- 多变量模型中放疗时机是PFS最强的独立预测因素,但其效应随时间减弱。
- 核分裂计数和Ki-67指数与早期及长期PFS独立相关,男性、高龄和次全切除预测肿瘤相关死亡。
临床怎么用
- 对WHO 2级脑膜瘤患者,尤其全切术后,可考虑早期辅助放疗以改善无进展生存。
- 术后风险分层应结合放疗时机、核分裂计数、Ki-67指数、切除程度及患者因素。
- 早期放疗未显示总生存获益,需等待随机试验结果后再作最终推荐。
局限性
- 回顾性设计可能存在选择偏倚。
- 早期与晚期放疗的比较非随机分组。
- 结论需待随机试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The optimal timing of radiotherapy (RT) in patients with WHO grade 2 meningiomas remains controversial, particularly following gross total resection (GTR). This multicenter study compared long-term outcomes of early RT versus late RT, focusing on progression-free survival (PFS), overall survival (OS), and tumor-related mortality. METHODS AND MATERIALS: This retrospective multicenter cohort study included 263 adult patients with histopathologically confirmed WHO grade 2 meningiomas treated between 2005 and 2023. Patients were stratified by RT timing: early adjuvant RT after initial surgery versus late RT administered after radiologic or clinical progression. Outcomes were analyzed in the overall cohort and in a prespecified GTR subgroup. PFS and OS were estimated using the Kaplan-Meier method. Tumor-related mortality was assessed using cause-specific Cox and Fine-Gray competing-risk models. RESULTS: With a median follow-up exceeding 7 years, early RT was associated with a significant improvement in PFS compared with late RT. In the overall cohort, 10-year PFS was 84.8% with early RT versus 18.6% with late RT (p < 0.001). Among patients undergoing GTR, 10-year PFS remained high with early RT (89.3%) but declined markedly after late RT (18.8%; p < 0.001). RT timing was the strongest independent predictor of PFS in multivariable models, although its effect attenuated over time. Tumor-related mortality was approximately sixfold higher in the late RT group (16.7% vs 2.7%; p = 0.011), whereas all-cause mortality did not differ significantly (24.2% vs 14.7%; p = 0.198). Mitotic count and Ki-67 index were independently associated with early and long-term PFS, whereas male sex, older age, and subtotal resection predicted tumor-related mortality. CONCLUSIONS: Early RT provides a durable and clinically meaningful PFS benefit over late RT in WHO grade 2 meningiomas, including after GTR, without conferring an OS advantage. These findings emphasize the importance of RT timing and tumor biology in postoperative risk stratification and support consideration of early RT in selected patients, pending results from randomized trials.
引用
- Demircan V, Şentürk E, Tezcanlı E, et al. Outcomes of early versus late radiotherapy in grade 2 meningiomas: a National retrospective analysis from the TROD neuro-oncology group. J Neurooncol. 2026. PMID: 42086919. doi:10.1007/s11060-026-05590-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。